Houston nurses win national innovation prize for developing life-like training technology

winner, winner

A team of Houston nurses won a national innovation award for a new game-changing training tool. Photos via Texas Children's Hospital

A team of Houston nurses was awarded the 2022 American Nursing Association Innovation Award last month for an engaging training tool that has already helped their peers locally and in sub-Saharan Africa become better equipped at performing essential medical skills.

Michael Pickett, Jaime Choate, and Jeannie Eggers with Texas Children's Hospital along with Marilyn Hocken and Tadala Mulemba with Baylor College of Medicine took home the nurse-led team award and $50,000 monetary prize for developing a group of devices known as the RediStik Wearable Simulation Trainers.

Resembling a CPR dummy and accompanied by immersive videos and live feedback via Zoom, the devices were designed to teach nurses how to insert Port-a-Cath and Central Venous Catheters (CVC) and perform peripheral intravenous (PIV) therapies, which are used to administer fluids, draw blood, and deliver medications.

The multidisciplinary team with support from the Texas Children’s Innovative Solutions Council developed five products (in two skin tones) over the course of three years that today can be worn by trainees and replicate textured skin and subcutaneous tissue to provide a realistic training experience.

The accompanying training materials and videos are often filmed from the nurse's point of view and are easily accessible via YouTube or a QR code.

The tools have already been utilized by nurses throughout Texas Children's, as well as in Sub-Saharan Africa through the hospital's partnership with the Global HOPE (Hematology Oncology Pediatric Excellence) initiative.

According to the ANA, after training with the RediStik devices, 96 percent of surveyed nurses reported that they felt confident in starting PIV lines, compared to only 15 percent of surveyed nurses prior to training.

The funds from the award will allow the RediStik team to distribute the devices to additional health care systems and nursing schools within Houston and internationally, according to a statement from ANA. Funds can also be used to support translational research, development, prototyping, production, testing, and the implementation of the technology.

The award winners—which also includes Kasheta Jackson of Vidant Health who took home the individual prize—have one year to further develop their products and report their outcomes.

The ANA innovation awards are sponsored by medical device company Stryker. The RediStik devices were engineered and produced by Sawbones, a Washington-based anatomical medical training models company.

February was a big month for Texas Children's and BCM.

In addition to the honor from the ANA, BCM Drs. Maria Elena Bottazzi and Peter Hotez, co-directors of the Center for Vaccine Development at Texas Children’s Hospital, were also nominated for the 2022 Nobel Peace Prize for their development of a low-cost COVID vaccine.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston edtech company closes oversubscribed $3M seed round

fresh funding

Houston-based edtech company TrueLeap Inc. closed an oversubscribed seed round last month.

The $3.3 million round was led by Joe Swinbank Family Limited Partnership, a venture capital firm based in Houston. Gamper Ventures, another Houston firm, also participated with additional strategic partners.

TrueLeap reports that the funding will support the large-scale rollout of its "edge AI, integrated learning systems and last-mile broadband across underserved communities."

“The last mile is where most digital transformation efforts break down,” Sandip Bordoloi, CEO and president of TrueLeap, said in a news release. “TrueLeap was built to operate where bandwidth is limited, power is unreliable, and institutions need real systems—not pilots. This round allows us to scale infrastructure that actually works on the ground.”

True Leap works to address the digital divide in education through its AI-powered education, workforce systems and digital services that are designed for underserved and low-connectivity communities.

The company has created infrastructure in Africa, India and rural America. Just this week, it announced an agreement with the City of Kinshasa in the Democratic Republic of Congo to deploy a digital twin platform for its public education system that will allow provincial leaders to manage enrollment, staffing, infrastructure and performance with live data.

“What sets TrueLeap apart is their infrastructure mindset,” Joe Swinbank, General Partner at Joe Swinbank Family Limited Partnership, added in the news release. “They are building the physical and digital rails that allow entire ecosystems to function. The convergence of edge compute, connectivity, and services makes this a compelling global infrastructure opportunity.”

TrueLeap was founded by Bordoloi and Sunny Zhang and developed out of Born Global Ventures, a Houston venture studio focused on advancing immigrant-founded technology. It closed an oversubscribed pre-seed in 2024.

Texas space co. takes giant step toward lunar excavator deployment

Out of this world

Lunar exploration and development are currently hampered by the fact that the moon is largely devoid of necessary infrastructure, like spaceports. Such amenities need to be constructed remotely by autonomous vehicles, and making effective devices that can survive the harsh lunar surface long enough to complete construction projects is daunting.

Enter San Antonio-based Astroport Space Technologies. Founded in San Antonio in 2020, the company has become a major part of building plans beyond Earth, via its prototype excavator, and in early February, it completed an important field test of its new lunar excavator.

The new excavator is designed to function with California-based Astrolab's Flexible Logistics and Exploration (FLEX) rover, a highly modular vehicle that will perform a variety of functions on the surface of the moon.

In a recent demo, the Astroport prototype excavator successfully integrated with FLEX and proceeded to dig in a simulated lunar surface. The excavator collected an average of 207 lbs (94kg) of regolith (lunar surface dust) in just 3.5 minutes. It will need that speed to move the estimated 3,723 tons (3,378 tonnes) of regolith needed for a lunar spaceport.

After the successful test, both Astroport and Astrolab expressed confidence that the excavator was ready for deployment. "Leading with this successful excavator demo proves that our technology is no longer theoretical—it is operational," said Sam Ximenes, CEO of Astroport.

"This is the first of many implements in development that will turn Astrolab's FLEX rover into the 'Swiss Army Knife' of lunar construction. To meet the infrastructure needs of the emerging lunar economy, we must build the 'Port' before the 'Ship' arrives. By leveraging the FLEX platform, we are providing the Space Force, NASA, and commercial partners with a 'Shovel-Ready' construction capability to secure the lunar high ground."

"We are excited to provide the mobility backbone for Astroport's groundbreaking construction technology," said Jaret Matthews, CEO of Astrolab, in a release. "Astrolab is dedicated to establishing a viable lunar ecosystem. By combining our FLEX rover's versatility with Astroport's civil engineering expertise, we are delivering the essential capabilities required for a sustainable lunar economy."

---

This article originally appeared on CultureMap.com.

Houston biotech co. raises $11M to advance ALS drug development

drug money

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.

View All Listings